Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Overview of attention for article published in Gastroenterology, September 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 14 news outlets
twitter: 24 X users
patent: 2 patents

facebook: 1 Facebook page
reddit: 1 Redditor
guideline: 3 clinical guideline sources

Readers on

mendeley: 70 Mendeley

So far, Altmetric has seen 28 X posts from 24 X users, with an upper bound of 109,771 followers.

RT @AGA_Gastro: In the QUASAR Phase 2b Induction study in patients with moderately to severely active ulcerative #colitis (N=313), week-12…

In the QUASAR Phase 2b Induction study in patients with moderately to severely active ulcerative #colitis (N=313), week-12 clinical response percentage was greater with guselkumab 200 mg (61.4%) and 400 mg (60.7%) versus placebo (27.6%; both P<.001) ➡️…

RT @IBDimmunology: Lots of new meds, finally got to Guselkumab in @AGA_Gastro ▶️anti-p19 abs, p2b, induction in UC ▶️prior anti-IL-23 use…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 24 additional X posts.